July 3, 2002 Long-term follow-up of the Heart and Estrogen/Progesterone Replacement Study (HERS II) reported in the July 3 issue of The Journal of the American Medical Association does not support the cardiovascular benefit once attributed to hormone replacement therapy (HRT).
Furthermore, HRT was linked to increased risk of venous thromboembolism and biliary tract surgery.
“This follow-up study found no reduction in risk of heart attacks or death for women with heart disease during up to seven years of hormone therapy,” lead author Deborah Grady, MD, MPH, from the University of California, San Francisco, says in a news release.
“Not only was there no cardiovascular benefit, there were adverse affects, including blood clots and gallbladder disease.” HERS was a randomized, blinded, placebo-controlled trial of estrogen plus progestin in older postmenopausal women with heart disease. Contrary to expectation, risk of myocardial infarction (MI) increased during the first year of HRT, although risk seemed to decrease during the remainder of the study, which lasted 4.1 years. The HERS II follow-up open-label study, lasting 2.7 years, was therefore designed to evaluate the effects of longer-duration HRT.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!